Windward Bio secured a $165 million financing to advance a long-acting anti-TSLP antibody into Phase 3 development for asthma. The Swiss biotech said the capital supports late-stage progress for a twice-yearly dosing strategy intended to differentiate in a crowded respiratory market. The funding arrives as asthma drug developers increasingly focus on longer-interval regimens and payer-friendly dosing profiles. Windward’s approach centers on extending dosing while maintaining clinical effect. The financing was described as a “crossover” round, reflecting investor appetite for late-stage runway tied to differentiation rather than only early biology. Windward’s disclosure also suggests a near-term catalyst calendar as it pushes toward pivotal readouts that would determine if the program can sustain efficacy across relevant patient subgroups.